You are here

Generic Version of Zithromax Gains FDA Approval

SCHAUMBURG, Ill., Dec. 14 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. (NASDAQ:APPX) , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Azithromycin for Injection, the generic equivalent of Pfizer Inc.'s Zithromax(R). Sales of this product exceeded $69 million in 2004 and were more than $74 million through the first nine months of 2005, according to IMS. APP expects to commence marketing Azithromycin in the 2006 first quarter, with GPO contracts in place.

"The addition of Azithromycin expands our anti-infective portfolio to 18 products and extends to 11 the number of different classes of anti-infectives APP offers," said Patrick Soon-Shiong, M.D., chairman and chief executive officer. "Azithromycin is the sixth multi-source product approval APP has received this year."

Azithromycin will be available from APP in 500 mg vials. The product is preservative-free and AP rated and each vial will include a bar code and latex-free vial stopper.

Azithromycin for Injection is indicated for the treatment of community-acquired pneumonia and pelvic inflammatory disease, when caused by susceptible microorganisms.

Source: American Pharmaceutical Partners, Inc.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile